Navigation Links
Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
Date:5/5/2008

ncial rights, moved forward with GSK's announcement of plans to advance darapladib to Phase 3 development for the treatment of atherosclerosis."

FINANCIAL RESULTS

HGS reported increased revenues for the quarter ended March 31, 2008 of $12.3 million, compared with revenues of $9.3 million for the same period in 2007. Revenues included $8.9 million recognized from the Albuferon agreement with Novartis, and $1.6 million in revenue recognized from the LymphoStat-B agreement with GlaxoSmithKline (GSK).

The Company reported a net loss for the quarter ended March 31, 2008 of $46.9 million ($0.35 per share), compared with a net loss for the first quarter of 2007 of $51.0 million ($0.38 per share).

Net cash burn for the three months ended March 31, 2008 totaled $36.1 million, net of $47.3 million received from Teva Pharmaceutical Industries Ltd., in partial payment for CoGenesys, Inc. stock previously owned by HGS.

As of March 31, 2008, cash and investments totaled $591.3 million, of which $519.0 million is unrestricted and available for operations. This compares with cash and investments totaling $603.8 million, of which $532.9 million was unrestricted and available for operations, as of December 31, 2007.

"Our cash position remains strong and our 2008 net cash burn is on track for $135-155 million as previously guided," said Tim Barabe, Senior Vice President and Chief Financial Officer, HGS.

HIGHLIGHTS OF RECENT PROGRESS

LymphoStat-B(R): Phase 3 Enrollment for BLISS-52 Completed; First Phase 3 Data Expected by Mid-2009

In April 2008, HGS announced the completion of enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus (SLE). Completion of enrollment for the other pivotal Phase 3 trial, BLISS-76, is expected by the end of summer 2008. HGS now expects to have the first Phase 3 data for LymphoStat-B ava
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
2. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
3. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results
4. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
5. Human Genome Sciences Advances Oncology Portfolio
6. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
7. Human Pheromone Sciences Announces Quarterly and Full Year Results
8. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
9. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... 2014 Research and Markets has ... Industry Report 2014" report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... human albumin market analysis is provided for the international ...
(Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s Flametec ... competitive in the semiconductor, clean room and medical ... product quality and productivity, according to Dwight Leatherwood, ... 1980 in Lewisville, TX, Leatherwood Plastics ... the business. Much of Leatherwood’s equipment building relies ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... pirfenidone role in treatment of patients with IPF -- Ground-breaking ... Strong data from 14-day triple combination study of ITMN-191 in ... (Nasdaq: ITMN ) today announced results from operations ... InterMune reported a net loss for the first quarter ...
... ERES ), a leading provider of centralized ECG, ... device, and related industries, announced today results for the first ... refer to changes from the same period a year ago.Highlights ... , Quarterly ...
... 30 Resonant Medical, an innovator in 3D ... appointment of Stephen Whisenhunt to the position of ... will lead the Company,s growing global sales team ... than 18 years of radiation oncology industry experience ...
Cached Biology Technology:InterMune Reports First Quarter 2009 Financial Results and Business Highlights 2InterMune Reports First Quarter 2009 Financial Results and Business Highlights 3InterMune Reports First Quarter 2009 Financial Results and Business Highlights 4InterMune Reports First Quarter 2009 Financial Results and Business Highlights 5InterMune Reports First Quarter 2009 Financial Results and Business Highlights 6InterMune Reports First Quarter 2009 Financial Results and Business Highlights 7InterMune Reports First Quarter 2009 Financial Results and Business Highlights 8InterMune Reports First Quarter 2009 Financial Results and Business Highlights 9InterMune Reports First Quarter 2009 Financial Results and Business Highlights 10InterMune Reports First Quarter 2009 Financial Results and Business Highlights 11InterMune Reports First Quarter 2009 Financial Results and Business Highlights 12InterMune Reports First Quarter 2009 Financial Results and Business Highlights 13ERT Reports First Quarter 2009 Results 2ERT Reports First Quarter 2009 Results 3ERT Reports First Quarter 2009 Results 4ERT Reports First Quarter 2009 Results 5ERT Reports First Quarter 2009 Results 6ERT Reports First Quarter 2009 Results 7ERT Reports First Quarter 2009 Results 8ERT Reports First Quarter 2009 Results 9Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing 2
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... and Duke University have developed nanoscale "patches" that can ... more responsive to signals that control cell activity. The ... engineering research. The research takes advantage of the ... via physical contact. Specifically, when targeted receptors on the ...
... mainland - are taking the lead in making plans to ... Diana Reckien, of Columbia University in the US, in a ... analysed the relevant strategic policies and planning documents of 200 ... in every three European cities has no plans on the ...
... "smart": too elementary to be able to reproduce by themselves, ... of their own DNA so that it is transcribed by ... inject their own genetic material into the cells they infect. ... (the International School for Advanced Studies in Trieste), has studied ...
Cached Biology News:Researchers use nanoscale 'patches' to sensitize targeted cell receptors 2The reality behind Europe's response to climate change 2Tidy knots are faster 2
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
...
Biology Products: